No. of PYs | Any psoriasis | Psoriasis vulgaris | Palmoplantar pustulosis | Arthropathic psoriasis | |||||
---|---|---|---|---|---|---|---|---|---|
Total/case no. | HR (95% CI) | Case no. | HR (95% CI) | Case no. | HR (95% CI) | Case no. | HR (95% CI) | ||
Overall | |||||||||
Matched reference cohort | 1,666,038 | 280,854/2795 | 1.00 (Ref.) | 1234 | 1.00 (Ref.) | 488 | 1.00 (Ref.) | 433 | 1.00 (Ref.) |
Breast cancer cohort | 307,684.8 | 56,235/599 | 1.17 (1.07–1.28) | 298 | 1.33 (1.17–1.52) | 95 | 1.04 (0.84–1.30) | 75 | 0.94 (0.73–1.20) |
Time since diagnosis | |||||||||
0 to < 0.5 year | |||||||||
Matched reference cohort | 139,886.5 | 280,854/238 | 1.00 (Ref.) | 86 | 1.00 (Ref.) | 48 | 1.00 (Ref.) | 51 | 1.00 (Ref.) |
Breast cancer cohort | 27,780.35 | 56,235/50 | 1.08 (0.80–1.47) | 23 | 1.35 (0.85–2.14) | 13 | 1.40 (0.76–2.59) | 4 | 0.41 (0.15–1.13) |
0.5 to < 1 year | |||||||||
Matched reference cohort | 138,587.1 | 278,473/228 | 1.00 (Ref.) | 113 | 1.00 (Ref.) | 27 | 1.00 (Ref.) | 32 | 1.00 (Ref.) |
Breast cancer cohort | 27,301.1 | 55,033/75 | 1.68 (1.30–2.19) | 37 | 1.66 (1.15–2.41) | 15 | 2.88 (1.52–5.43) | 5 | 0.80 (0.31–2.07) |
1–5 years | |||||||||
Matched reference cohort | 861,202.7 | 275,870/1451 | 1.00 (Ref.) | 629 | 1.00 (Ref.) | 281 | 1.00 (Ref.) | 219 | 1.00 (Ref.) |
Breast cancer cohort | 162,011.6 | 54,156/296 | 1.09 (0.96–1.24) | 146 | 1.27 (1.06–1.52) | 43 | 0.81 (0.58–1.12) | 44 | 1.07 (0.77–1.48) |
> 5 years | |||||||||
Matched reference cohort | 526,362 | 159,147/878 | 1.00 (Ref.) | 406 | 1.00 (Ref.) | 132 | 1.00 (Ref.) | 131 | 1.00 (Ref.) |
Breast cancer cohort | 90,591.81 | 28,430/178 | 1.17 (0.99–1.38) | 92 | 1.33 (1.06–1.68) | 24 | 1.02 (0.66–1.60) | 22 | 0.98 (0.62–1.56) |
Age at breast cancer diagnosis | |||||||||
20–44 years | |||||||||
Matched reference cohort | 158,527.2 | 25,361/185 | 1.00 (Ref.) | 75 | 1.00 (Ref.) | 30 | 1.00 (Ref.) | 46 | 1.00 (Ref.) |
Breast cancer cohort | 28,908.36 | 5099/43 | 1.35 (0.97–1.90) | 24 | 1.88 (1.17–3.00) | 6 | 1.08 (0.45–2.62) | 6 | 0.82 (0.35–1.94) |
45–54 years | |||||||||
Matched reference cohort | 389,187.5 | 61,404/707 | 1.00 (Ref.) | 285 | 1.00 (Ref.) | 155 | 1.00 (Ref.) | 122 | 1.00 (Ref.) |
Breast cancer cohort | 72,753.48 | 12,289/151 | 1.16 (0.97–1.38) | 72 | 1.39 (1.07–1.81) | 28 | 0.95 (0.63–1.43) | 22 | 0.97 (0.61–1.53) |
55–64 years | |||||||||
Matched reference cohort | 549,425.4 | 89,347/1067 | 1.00 (Ref.) | 447 | 1.00 (Ref.) | 213 | 1.00 (Ref.) | 172 | 1.00 (Ref.) |
Breast cancer cohort | 102,753.2 | 17,850/229 | 1.14 (0.99–1.32) | 109 | 1.27 (1.03–1.58) | 42 | 1.04 (0.74–1.45) | 23 | 0.74 (0.47–1.15) |
65–80 years | |||||||||
Matched reference cohort | 568,898.3 | 104,742/836 | 1.00 (Ref.) | 427 | 1.00 (Ref.) | 90 | 1.00 (Ref.) | 93 | 1.00 (Ref.) |
Breast cancer cohort | 103,269.8 | 20,997/176 | 1.16 (0.99–1.38) | 93 | 1.27 (1.01–1.59) | 19 | 1.21 (0.73–2.01) | 24 | 1.30 (0.82–2.07) |